Abstract
Cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality among patients receiving allogeneic bone marrow transplantation. Pneumonia is the most serious manifestation, with an incidence of 15% to 30%. Although the use of ganciclovir with intravenous immunoglobulin has improved survival, CMV pneumonitis is often fatal, underscoring the need for effective prophylaxis.
| Original language | English |
|---|---|
| Pages (from-to) | 258+261-262 |
| Journal | Infections in Medicine |
| Volume | 11 |
| Issue number | 4 |
| State | Published - 1994 |
| Externally published | Yes |
Keywords
- cancer
- cytomegalovirus (CMV)
- ganciclovir
- immunoglobulin
- pneumonitis